Payment overview · 2025
General Payments
$355.18
13 reported records · 10 companies
Healthcare provider profile · identity verified
Abdul Ghaffar Durrani, MD
Allopathic & Osteopathic Physicians|Hospitalist · KENOSHA, WI · NPI 1306833686
Verified facts
What the public records show
CMS Open Payments records show Abdul Ghaffar Durrani, MD received $355.18 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.46 | 49.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.71 | 10.3% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.99 | 5.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.80 | 5.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.88 | 5.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.45 | 4.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.35 | 4.9% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $15.88 | 4.5% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.31 | 4.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.35 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.18 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $176.46 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 353 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 54 |
| Losartan Potassium | Losartan Potassium | 275 | 66 |
| Gabapentin | Gabapentin | 204 | 38 |
| Furosemide | Furosemide | 202 | 41 |
| Metformin Hcl | Metformin Hcl | 187 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 46 |
| Omeprazole | Omeprazole | 164 | 39 |
| Lisinopril | Lisinopril | 159 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 157 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 42 |
| Sertraline Hcl | Sertraline Hcl | 123 | 20 |
| Simvastatin | Simvastatin | 120 | 32 |
| Potassium Chloride | Potassium Chloride | 114 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 24 |
| Alprazolam | Alprazolam | 91 | 17 |
| Prednisone | Prednisone | 91 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 15 |
| Glimepiride | Glimepiride | 86 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 18 |
| Eliquis | Apixaban | 79 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 17 |
| Mirtazapine | Mirtazapine | 76 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 19 |
| Trazodone Hcl | Trazodone Hcl | 68 | 13 |
| Divalproex Sodium | Divalproex Sodium | 67 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | suppressed |
| Lorazepam | Lorazepam | 62 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 15 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Allopurinol | Allopurinol | 52 | 12 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 12 |
| Carvedilol | Carvedilol | 47 | 11 |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Latanoprost | Latanoprost | 46 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 36 |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 13 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Famotidine | Famotidine | 35 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Invokana | Canagliflozin | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 22 |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 19 |
| Diazepam | Diazepam | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Leflunomide | Leflunomide | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Concerta | Methylphenidate Hcl | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Plavix | Clopidogrel Bisulfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.18 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, PURIFIED CORTROPHIN GEL, Paradise Ultrasound Renal Denervation System, REXULTI, UBRELVY, Wegovy, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error